Major depression and treatment response in adolescents with ADHD and substance use disorder

Diane Warden, Paula D. Riggs, Sung Joon Min, Susan K. Mikulich-Gilbertson, Leanne Tamm, Kathlene Trello-Rishel, Theresa Winhusen

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Background: Major depressive disorder (MDD) frequently co-occurs in adolescents with substance use disorders (SUDs) and attention deficit hyperactivity disorder (ADHD), but the impact of MDD on substance treatment and ADHD outcomes and implications for clinical practice are unclear. Methods: Adolescents (n = 303; ages 13-18) meeting DSM-IV criteria for ADHD and SUD were randomized to osmotic release methylphenidate (OROS-MPH) or placebo and 16 weeks of cognitive behavioral therapy (CBT). Adolescents with (n = 38) and without (n = 265) MDD were compared on baseline demographic and clinical characteristics as well as non-nicotine substance use and ADHD treatment outcomes. Results: Adolescents with MDD reported more non-nicotine substance use days at baseline and continued using more throughout treatment compared to those without MDD (p< 0.0001 based on timeline followback; p< 0.001 based on urine drug screens). There was no difference between adolescents with and without MDD in retention or CBT sessions attended. ADHD symptom severity (based on DSM-IV ADHD rating scale) followed a slightly different course of improvement although with no difference between groups in baseline or 16-week symptom severity or 16-week symptom reduction. There was no difference in days of substance use or ADHD symptom outcomes over time in adolescents with MDD or those without MDD treated with OROS-MPH or placebo. Depressed adolescents were more often female, older, and not court ordered. Conclusions: These preliminary findings suggest that compared to non-depressed adolescents with ADHD and SUD, those with co-occurring MDD have more severe substance use at baseline and throughout treatment. Such youth may require interventions targeting depression.

Original languageEnglish (US)
Pages (from-to)214-219
Number of pages6
JournalDrug and Alcohol Dependence
Volume120
Issue number1-3
DOIs
StatePublished - Jan 1 2012

Fingerprint

Major Depressive Disorder
Attention Deficit Disorder with Hyperactivity
Substance-Related Disorders
Depression
Methylphenidate
Therapeutics
Cognitive Therapy
Pharmaceutical Preparations
Diagnostic and Statistical Manual of Mental Disorders
Placebos
5,10-dihydro-5-methylphenazine
Demography
Urine
TimeLine

Keywords

  • Adolescents
  • Attention deficit hyperactivity disorder
  • Comorbid disorder
  • Major depressive disorder
  • Substance use disorder
  • Treatment outcomes

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Toxicology
  • Pharmacology
  • Pharmacology (medical)

Cite this

Major depression and treatment response in adolescents with ADHD and substance use disorder. / Warden, Diane; Riggs, Paula D.; Min, Sung Joon; Mikulich-Gilbertson, Susan K.; Tamm, Leanne; Trello-Rishel, Kathlene; Winhusen, Theresa.

In: Drug and Alcohol Dependence, Vol. 120, No. 1-3, 01.01.2012, p. 214-219.

Research output: Contribution to journalArticle

Warden, Diane ; Riggs, Paula D. ; Min, Sung Joon ; Mikulich-Gilbertson, Susan K. ; Tamm, Leanne ; Trello-Rishel, Kathlene ; Winhusen, Theresa. / Major depression and treatment response in adolescents with ADHD and substance use disorder. In: Drug and Alcohol Dependence. 2012 ; Vol. 120, No. 1-3. pp. 214-219.
@article{51840d39fe7548448078c5840ecc4498,
title = "Major depression and treatment response in adolescents with ADHD and substance use disorder",
abstract = "Background: Major depressive disorder (MDD) frequently co-occurs in adolescents with substance use disorders (SUDs) and attention deficit hyperactivity disorder (ADHD), but the impact of MDD on substance treatment and ADHD outcomes and implications for clinical practice are unclear. Methods: Adolescents (n = 303; ages 13-18) meeting DSM-IV criteria for ADHD and SUD were randomized to osmotic release methylphenidate (OROS-MPH) or placebo and 16 weeks of cognitive behavioral therapy (CBT). Adolescents with (n = 38) and without (n = 265) MDD were compared on baseline demographic and clinical characteristics as well as non-nicotine substance use and ADHD treatment outcomes. Results: Adolescents with MDD reported more non-nicotine substance use days at baseline and continued using more throughout treatment compared to those without MDD (p< 0.0001 based on timeline followback; p< 0.001 based on urine drug screens). There was no difference between adolescents with and without MDD in retention or CBT sessions attended. ADHD symptom severity (based on DSM-IV ADHD rating scale) followed a slightly different course of improvement although with no difference between groups in baseline or 16-week symptom severity or 16-week symptom reduction. There was no difference in days of substance use or ADHD symptom outcomes over time in adolescents with MDD or those without MDD treated with OROS-MPH or placebo. Depressed adolescents were more often female, older, and not court ordered. Conclusions: These preliminary findings suggest that compared to non-depressed adolescents with ADHD and SUD, those with co-occurring MDD have more severe substance use at baseline and throughout treatment. Such youth may require interventions targeting depression.",
keywords = "Adolescents, Attention deficit hyperactivity disorder, Comorbid disorder, Major depressive disorder, Substance use disorder, Treatment outcomes",
author = "Diane Warden and Riggs, {Paula D.} and Min, {Sung Joon} and Mikulich-Gilbertson, {Susan K.} and Leanne Tamm and Kathlene Trello-Rishel and Theresa Winhusen",
year = "2012",
month = "1",
day = "1",
doi = "10.1016/j.drugalcdep.2011.08.001",
language = "English (US)",
volume = "120",
pages = "214--219",
journal = "Drug and Alcohol Dependence",
issn = "0376-8716",
publisher = "Elsevier Ireland Ltd",
number = "1-3",

}

TY - JOUR

T1 - Major depression and treatment response in adolescents with ADHD and substance use disorder

AU - Warden, Diane

AU - Riggs, Paula D.

AU - Min, Sung Joon

AU - Mikulich-Gilbertson, Susan K.

AU - Tamm, Leanne

AU - Trello-Rishel, Kathlene

AU - Winhusen, Theresa

PY - 2012/1/1

Y1 - 2012/1/1

N2 - Background: Major depressive disorder (MDD) frequently co-occurs in adolescents with substance use disorders (SUDs) and attention deficit hyperactivity disorder (ADHD), but the impact of MDD on substance treatment and ADHD outcomes and implications for clinical practice are unclear. Methods: Adolescents (n = 303; ages 13-18) meeting DSM-IV criteria for ADHD and SUD were randomized to osmotic release methylphenidate (OROS-MPH) or placebo and 16 weeks of cognitive behavioral therapy (CBT). Adolescents with (n = 38) and without (n = 265) MDD were compared on baseline demographic and clinical characteristics as well as non-nicotine substance use and ADHD treatment outcomes. Results: Adolescents with MDD reported more non-nicotine substance use days at baseline and continued using more throughout treatment compared to those without MDD (p< 0.0001 based on timeline followback; p< 0.001 based on urine drug screens). There was no difference between adolescents with and without MDD in retention or CBT sessions attended. ADHD symptom severity (based on DSM-IV ADHD rating scale) followed a slightly different course of improvement although with no difference between groups in baseline or 16-week symptom severity or 16-week symptom reduction. There was no difference in days of substance use or ADHD symptom outcomes over time in adolescents with MDD or those without MDD treated with OROS-MPH or placebo. Depressed adolescents were more often female, older, and not court ordered. Conclusions: These preliminary findings suggest that compared to non-depressed adolescents with ADHD and SUD, those with co-occurring MDD have more severe substance use at baseline and throughout treatment. Such youth may require interventions targeting depression.

AB - Background: Major depressive disorder (MDD) frequently co-occurs in adolescents with substance use disorders (SUDs) and attention deficit hyperactivity disorder (ADHD), but the impact of MDD on substance treatment and ADHD outcomes and implications for clinical practice are unclear. Methods: Adolescents (n = 303; ages 13-18) meeting DSM-IV criteria for ADHD and SUD were randomized to osmotic release methylphenidate (OROS-MPH) or placebo and 16 weeks of cognitive behavioral therapy (CBT). Adolescents with (n = 38) and without (n = 265) MDD were compared on baseline demographic and clinical characteristics as well as non-nicotine substance use and ADHD treatment outcomes. Results: Adolescents with MDD reported more non-nicotine substance use days at baseline and continued using more throughout treatment compared to those without MDD (p< 0.0001 based on timeline followback; p< 0.001 based on urine drug screens). There was no difference between adolescents with and without MDD in retention or CBT sessions attended. ADHD symptom severity (based on DSM-IV ADHD rating scale) followed a slightly different course of improvement although with no difference between groups in baseline or 16-week symptom severity or 16-week symptom reduction. There was no difference in days of substance use or ADHD symptom outcomes over time in adolescents with MDD or those without MDD treated with OROS-MPH or placebo. Depressed adolescents were more often female, older, and not court ordered. Conclusions: These preliminary findings suggest that compared to non-depressed adolescents with ADHD and SUD, those with co-occurring MDD have more severe substance use at baseline and throughout treatment. Such youth may require interventions targeting depression.

KW - Adolescents

KW - Attention deficit hyperactivity disorder

KW - Comorbid disorder

KW - Major depressive disorder

KW - Substance use disorder

KW - Treatment outcomes

UR - http://www.scopus.com/inward/record.url?scp=84155167324&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84155167324&partnerID=8YFLogxK

U2 - 10.1016/j.drugalcdep.2011.08.001

DO - 10.1016/j.drugalcdep.2011.08.001

M3 - Article

VL - 120

SP - 214

EP - 219

JO - Drug and Alcohol Dependence

JF - Drug and Alcohol Dependence

SN - 0376-8716

IS - 1-3

ER -